EUVIMEDEUVIMED entdecken
Crossref

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura

Qing Wen, Jia Chen, Ting Sun, Xiyan Wang, Mankai Ju, Xiaofan Liu, Huiyuan Li, Rongfeng Fu, Wei Liu, Feng Xue, Huan Dong, Xinyue Dai und 5 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Qing Wen und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Ke…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Proteomics, Membrane Proteins, Bone Marrow. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy, with a substantial risk of relapse despite advances in therapy. Robust biomarkers to predict relapse are urgently needed to inform risk-adapted management. This study represents the first application of bone marrow proteomic profiling in TTP to explore relapse-associated biomarkers. OBJECTIVES: To identify clinical risk factors and novel protein biomarkers for relapse in TTP through integrated clinical and bone marrow proteomic analyses. METHODS: We conducted a retrospective cohort study involving 123 patients diagnosed with TTP at a single center. Clinical and laboratory variables at initial presentation were analyzed to identify potential predictors of relapse using Cox proportional hazards models. To explore molecular correlates of relapse, bone marrow paraffin-embedded samples from 18 patients were subjected to quantitative proteomic profiling. Machine learning algorithms were applied to identify candidate relapse-associated proteins. Selected proteins were subsequently validated by immunohistochemistry of corresponding tissue sections. RESULTS: Age ≤30 years and severe neuropsychiatric symptoms were independently associated with increased relapse risk, but demonstrated only moderate predictive performance (area under the curve = 0.706). Proteomic profiling revealed TMEM109 as a relapse-associated protein with superior discriminative capacity (area under the curve = 0.929). Immunohistochemistry analysis confirmed reduced TMEM109 expression in relapsed patients (P < .0001). CONCLUSION: TMEM109 is a promising biomarker for predicting TTP relapse. While clinical factors such as age and neuropsychiatric symptoms provide valuable prognostic information, TMEM109 may enhance relapse-risk stratification, offering potential for individualized monitoring and therapeutic decision-making. These findings underscore the value of proteomic profiling in complementing clinical evaluation in TTP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicProteomicsMembrane ProteinsBone MarrowHumansFemaleRecurrenceBiomarkersRetrospective StudiesAdultMaleRisk FactorsMiddle AgedProportional Hazards ModelsYoung AdultImmunohistochemistryPredictive Value of TestsMachine LearningArea Under CurvePrognosis

Stichwörter der Autor:innen

TMEM109agerelapsethrombotic thrombocytopenic purpura

Substanzen

Membrane ProteinsBiomarkers

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Chinese Academy of Me…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Zitieren

APA

Wen, Q., Chen, J., Sun, T., Wang, X., Ju, M., Liu, X., Li, H., Fu, R., Liu, W., Xue, F., Dong, H., Dai, X., Wang, W., Chi, Y., Yang, R., Chen, Y., & Zhang, L. (2026). Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.01.003

Vancouver

Wen Q, Chen J, Sun T, Wang X, Ju M, Liu X, et al. Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.01.003

BibTeX
@article{Wen2026,
  author = {Wen, Qing and Chen, Jia and Sun, Ting and Wang, Xiyan and Ju, Mankai and Liu, Xiaofan and Li, Huiyuan and Fu, Rongfeng and Liu, Wei and Xue, Feng and Dong, Huan and Dai, Xinyue and Wang, Wentian and Chi, Ying and Yang, Renchi and Chen, Yunfei and Zhang, Lei},
  title = {Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.01.003}
}
Kostenlos starten →